Biotech Values

[jq1234]

"In general" discussion is useless in this case. Given Viekira's benign safety profile, I wouldn't pay extra $10-$20K to take Harvoni over Viekira IF I PAY MYSELF for drugs. If everyone pays his/her own drug directly rather than insurance, majority will make same choice as I do in this case. This isn't a choice between chemo docetaxel and immunotherapy Opdivo/Keytruda where AE profiles are night and day. That's where the balance was lost by the group. If ESRX hadn't taken hard line in this case, the outcome would have been different from GILD.

I am for free market control of drug price in US, rather than so many so called free marketers favoring monopoly rather than competition.